We help clinicians make more informed decisions

about their patients’ kidney health.

FACT 1

Current kidney function measurements (eGFR and UACR) can diagnose kidney disease but they cannot predict which patients are at higher vs lower risk for rapid progressive decline in kidney function or kidney failure.

FACT 2

Now, there is a laboratory-developed test (LDT), KidneyIntelXTM, validated in two large cohorts, to be a highly-reliable, bioprognosticTM methodology, that yields a simple-to-understand, custom risk score, predicting which adult patients with type 2 diabetes and with chronic kidney disease stages 1-3b are at low, intermediate or high risk for rapid progressive decline in kidney function.

FACT 3

When clinicians combine information gathered through KidneyIntelX with newer cardio- and reno-protective therapies, it’s a win-win. They will know which patients are at higher to lower risk for rapid disease progression, and therefore, can appropriately target resources and medications shown to be more effective at slowing or preempting disease progression and advancing kidney health.

FACT 4

KidneyIntelX is used in stages 1-3b, when it’s most critical. That’s because 90% of patients are unaware that they even have chronic kidney disease in earlier stages, as it is largely asymptomatic at that time. And, clinicians are largely unaware that early-stage patients (stages 1-3b) can experience rapid progressive decline in kidney function.

FACT 5

Finally, clinicians can successfully manage patient risk in time to make a real difference…for kidney health and for overall wellbeing.

FACT 6

KidneyIntelX has received FDA Breakthrough Device Designation and is seeking FDA De Novo marketing authorization.

About Test
See Evidence

We must act with intent and urgency.

Nearly 40 million

# of early-stage chronic kidney disease (CKD) patients in the U.S.

Kidney disease affects more people than cancer and heart disease combined.

https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html

At least 14 million

the # of CKD patients with diabetes

https://www.kidney.org/atoz/content/diabetes

But only 52%

of clinicians routinely perform CKD testing in their diabetes patients, largely because it is asymptomatic.

Did you know?

The ADA recommends screening for DKD annually.

Because of the increasing number of diabetes patients with kidney disease (DKD), the American Diabetes Association recently updated their guidelines. Among other things, they recommend that urinary albumin and estimated glomerular filtration rate be assessed in all patients with type 2 diabetes annually.

Once you know who has DKD,

understand the risk

for its progression.

Reliably, efficiently, more simply.

After your adult patients with type 2 diabetes also test positive for chronic kidney disease, you’ll still and with chronic kidney disease are screened for kidney disease, you’ll still need to identify which of those patients will need lower-level maintenance or ongoing monitoring or immediate lifestyle and therapeutic adjustments and referrals to a specialist.

KidneyIntelX yields a clinically-validated, simple-to-understand, custom risk score, identifying adult patients with type 2 diabetes and with chronic kidney disease in stages 1-3b who are at low, intermediate or high risk for kidney disease progression over the next five years.

Low Risk Result

(5 to 45)

Approximately 50% of patients tested with KidneyIntelX are expected to receive a low-risk score. A low-risk score (“green”) means that your adult patient with type 2 diabetes and chronic kidney disease stages 1-3b, is at the lowest risk for progressive decline in kidney function. Clinical studies have shown that the risk that an individual with this score will experience such a decline over the next five years is < 10%.

Intermediate Risk Result

(50 to 85)

Approximately 35% of all patients tested with KidneyIntelX are expected to receive an intermediate risk score. With an intermediate-risk score (“orange”), you may recommend that the patient monitors his/her kidney health more frequently, which may include additional visits, additional blood work, some lifestyle changes and potentially, the introduction of specialized medication.

High Risk Result

(90 to 100)

Approximately 15% of patients tested with KidneyIntelX are expected to receive a high-risk score, which means that they have a 60% or higher chance of experiencing progressive decline in kidney function over the next five years. With a high-risk score, you may act more quickly and aggressively in the treatment of your patients’ kidney disease, which could include more frequent follow-up visits, referrals to a nephrologist, maximizing current medications and/or introducing new medications.

Order Test
About Test
Indication For Use
Important Risk Information
Why Early Stage Risk Assessment